Biofrontera (BFRI) Free Cash Flow Growth (3y) (2023 - 2025)
Biofrontera (BFRI) Free Cash Flow Growth (3y) (2023 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.56 Bn | 12.13 Bn | 785.00 Mn | 39.19% |
| 10 | Biofrontera | 10.99 Mn | 4.58 Mn | 14.09 Mn | 33.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 33.75% |
| Sep 30, 2025 | 13.83% |
| Jun 30, 2025 | -240.88% |
| Mar 31, 2025 | -25.09% |
| Dec 31, 2024 | 63.75% |
| Sep 30, 2024 | -1.76% |
| Jun 30, 2024 | -61.84% |
| Mar 31, 2024 | 0.42% |
| Dec 31, 2023 | -133.69% |